Insider transactions

EDGAR

COGENT BIOSCIENCES, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
8 transactions, 10,860,152 shares
Sum of shares × price per share: 383,888,198.3581

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 50

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-01 Filed 2026-10-05Ferrante Karen Jean Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (759) — exercise price 31.59
Acquired (A)7590—759Direct (D) No
F1
  • F1 The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001193125-26-414218 Read from the filing’s XML Dispute this row
2026-08-27 Filed 2026-08-31Morris Arlene Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)41,9275.64
236,468.28

Derived: shares × price per share. Exact value 236468.28.

41,927Direct (D) Yes
F1
  • F1 Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.
Open filing 0001193125-26-377001 Read from the filing’s XML Dispute this row
2026-08-27 Filed 2026-08-31Morris Arlene Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,5832.52
9,029.16

Derived: shares × price per share. Exact value 9029.16.

45,510Direct (D) Yes
F1
  • F1 Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.
Open filing 0001193125-26-377001 Read from the filing’s XML Dispute this row
2026-08-27 Filed 2026-08-31Morris Arlene Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)42,34937.0925
1,570,830.2825

Derived: shares × price per share. Exact value 1570830.2825.

3,161Direct (D) Yes
F1, F2
  • F1 Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.
  • F2 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $36.46 to $37.45. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open filing 0001193125-26-377001 Read from the filing’s XML Dispute this row
2026-08-27 Filed 2026-08-31Morris Arlene Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,16137.5396
118,662.6756

Derived: shares × price per share. Exact value 118662.6756.

0Direct (D) Yes
F1, F3
  • F1 Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.
  • F3 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $37.46 to $37.65. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open filing 0001193125-26-377001 Read from the filing’s XML Dispute this row
2026-08-27 Filed 2026-08-31Morris Arlene Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (41,927) — exercise price 5.64
Disposed (D)41,9270—2,773Direct (D) Yes
F1, F4
  • F1 Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.
  • F4 These options are fully vested.
Open filing 0001193125-26-377001 Read from the filing’s XML Dispute this row
2026-08-27 Filed 2026-08-31Morris Arlene Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (3,583) — exercise price 2.52
Disposed (D)3,5830—0Direct (D) Yes
F1, F4
  • F1 Transactions effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 28, 2026.
  • F4 These options are fully vested.
Open filing 0001193125-26-377001 Read from the filing’s XML Dispute this row
2026-07-01 Filed 2026-07-06Ferrante Karen Jean Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (627) — exercise price 38.48
Acquired (A)6270—627Direct (D) No
F1
  • F1 The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001193125-26-296249 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Harwin Peter Evan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (17,901) — exercise price 31.98
Acquired (A)17,9010—17,901Direct (D) No
F1, F2
  • F1 This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.
  • F2 Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the Adviser), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a Fairmount Fund). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
Open filing 0001193125-26-267665 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Ros Matthew Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (17,901) — exercise price 31.98
Acquired (A)17,9010—17,901Direct (D) No
F1
  • F1 This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.
Open filing 0001193125-26-267666 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Ferrante Karen Jean Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (17,901) — exercise price 31.98
Acquired (A)17,9010—17,901Direct (D) No
F1
  • F1 This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.
Open filing 0001193125-26-267663 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11CAIN CHRISTOPHER W. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (17,901) — exercise price 31.98
Acquired (A)17,9010—17,901Direct (D) No
F1, F2
  • F1 This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.
  • F2 Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the Adviser), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a Fairmount Fund). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
Open filing 0001193125-26-267662 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Shegog Todd Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (17,901) — exercise price 31.98
Acquired (A)17,9010—17,901Direct (D) No
F1
  • F1 This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.
Open filing 0001193125-26-267670 Read from the filing’s XML Dispute this row
2026-06-09 Filed 2026-06-11Morris Arlene Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (17,901) — exercise price 31.98
Acquired (A)17,9010—17,901Direct (D) No
F1
  • F1 This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.
Open filing 0001193125-26-267667 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21Robbins Andrew R Director · Officer: President and CEO
G

Bona fide gift

Common Stock
Disposed (D)160,0000—497,503Direct (D) No
F1
  • F1 On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes.
Open filing 0001193125-26-234578 Read from the filing’s XML Dispute this row
2026-05-19 Filed 2026-05-21Robbins Andrew R Director · Officer: President and CEO
G

Bona fide gift

Common Stock
Acquired (A)160,0000—160,000Indirect (I) By trustNo
F1
  • F1 On May 19, 2026, Mr. Robbins transferred 160,000 shares of common stock to a family trust for estate planning purposes.
Open filing 0001193125-26-234578 Read from the filing’s XML Dispute this row
2026-04-01 Filed 2026-04-03Ferrante Karen Jean Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (686) — exercise price 35.24
Acquired (A)6860.00
0

Derived: shares × price per share. Exact value 0.00.

686Direct (D) No
F1
  • F1 The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001193125-26-142082 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-03-31Fairmount Funds Management LLC Director
C

Conversion of derivative security

Common Stock
Acquired (A)7,000,000——12,503,418Indirect (I) Fairmount Healthcare Fund II LPNo
F1, F2
  • F1 Each share of Series A Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 250 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On March 31, 2026, the Reporting Persons converted 28,000 shares of Series A Convertible Preferred Stock into 7,000,000 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series A Convertible Preferred Stock.
  • F2 Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP (Fund II). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
Open filing 0001104659-26-038057 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-03-31Fairmount Funds Management LLC Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)7,000,00034.66
242,620,000

Derived: shares × price per share. Exact value 242620000.00.

5,503,418Indirect (I) Fairmount Healthcare Fund II LPNo
F2
  • F2 Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP (Fund II). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
Open filing 0001104659-26-038057 Read from the filing’s XML Dispute this row
2026-03-31 Filed 2026-03-31Fairmount Funds Management LLC Director
C

Conversion of derivative security

Derivative security: Series A Convertible Preferred Stock — underlying Common Stock (7,000,000)
Disposed (D)28,0000.00
0

Derived: shares × price per share. Exact value 0.00.

39,414Indirect (I) Fairmount Healthcare Fund II LPNo
F1, F2
  • F1 Each share of Series A Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 250 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On March 31, 2026, the Reporting Persons converted 28,000 shares of Series A Convertible Preferred Stock into 7,000,000 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series A Convertible Preferred Stock.
  • F2 Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP (Fund II). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
Open filing 0001104659-26-038057 Read from the filing’s XML Dispute this row
2026-01-22 Filed 2026-01-22Fairmount Funds Management LLC Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,500,00036.40
127,400,000

Derived: shares × price per share. Exact value 127400000.00.

5,503,418Indirect (I) Fairmount Healthcare Fund II LPNo
F1
  • F1 Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP (Fund II). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
Open filing 0001104659-26-005924 Read from the filing’s XML Dispute this row
2026-01-01 Filed 2026-01-05Ferrante Karen Jean Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (643) — exercise price 34.74
Acquired (A)6430.00
0

Derived: shares × price per share. Exact value 0.00.

643Direct (D) No
F1
  • F1 The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
Open filing 0001193125-26-002367 Read from the filing’s XML Dispute this row
2025-12-26 Filed 2025-12-30Robinson John Edward Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)90,00038.74
3,486,600

Derived: shares × price per share. Exact value 3486600.00.

140,002Direct (D) No
F1, F2
  • F1 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.51 to $39.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F2 Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.
Open filing 0001193125-25-337049 Read from the filing’s XML Dispute this row
2025-12-26 Filed 2025-12-30Green John L. Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)77,00038.68
2,978,360

Derived: shares × price per share. Exact value 2978360.00.

131,834Direct (D) No
F1, F2
  • F1 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.51 to $38.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F2 Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.
Open filing 0001193125-25-337051 Read from the filing’s XML Dispute this row
2025-12-26 Filed 2025-12-30Kearns Evan Officer: Chief Legal Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)65,00038.70
2,515,500

Derived: shares × price per share. Exact value 2515500.00.

109,398Direct (D) No
F1, F2
  • F1 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.52 to $38.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F2 Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.
Open filing 0001193125-25-337052 Read from the filing’s XML Dispute this row
2025-12-26 Filed 2025-12-30Sachs Jessica Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)82,64238.70
3,198,245.4

Derived: shares × price per share. Exact value 3198245.40.

133,938Direct (D) No
F1, F2
  • F1 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.53 to $38.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • F2 Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.
Open filing 0001193125-25-337050 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Robbins Andrew R Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)185,0000—185,000Direct (D) No
F1
  • F1 Award of Restricted Stock Units (RSUs) under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.
Open filing 0001193125-25-326775 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Robbins Andrew R Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)840,0000—1,025,000Direct (D) No
F2
  • F2 Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the 2023 PSUs).
Open filing 0001193125-25-326775 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Robbins Andrew R Director · Officer: President and CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)367,49739.45
14,497,756.65

Derived: shares × price per share. Exact value 14497756.65.

657,503Direct (D) No
F3, F4
  • F3 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.
  • F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Open filing 0001193125-25-326775 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Robbins Andrew R Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (245,000) — exercise price 39.45
Acquired (A)245,0000.00
0

Derived: shares × price per share. Exact value 0.00.

245,000Direct (D) No
F5
  • F5 This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.
Open filing 0001193125-25-326775 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Pinnow Cole Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)50,0000—97,450Direct (D) No
F1, F2
  • F1 Award of Restricted Stock Units (RSUs) under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.
  • F2 Includes an aggregate of 1,602 shares of common stock acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan on June 30, 2025.
Open filing 0001193125-25-326774 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Pinnow Cole Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)214,0000—311,450Direct (D) No
F3
  • F3 Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the 2023 PSUs).
Open filing 0001193125-25-326774 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Pinnow Cole Officer: Chief Commercial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)94,80039.45
3,739,860

Derived: shares × price per share. Exact value 3739860.00.

216,650Direct (D) No
F4, F5
  • F4 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.
  • F5 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Open filing 0001193125-25-326774 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Pinnow Cole Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (65,000) — exercise price 39.45
Acquired (A)65,0000.00
0

Derived: shares × price per share. Exact value 0.00.

65,000Direct (D) No
F6
  • F6 This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.
Open filing 0001193125-25-326774 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Green John L. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)50,0000—53,841Direct (D) No
F1
  • F1 Award of Restricted Stock Units (RSUs) under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.
Open filing 0001193125-25-326771 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Green John L. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)300,0000—353,841Direct (D) No
F2
  • F2 Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the 2023 PSUs).
Open filing 0001193125-25-326771 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Green John L. Officer: Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)145,00739.45
5,720,526.15

Derived: shares × price per share. Exact value 5720526.15.

208,834Direct (D) No
F3, F4
  • F3 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.
  • F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Open filing 0001193125-25-326771 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Green John L. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (65,000) — exercise price 39.45
Acquired (A)65,0000.00
0

Derived: shares × price per share. Exact value 0.00.

65,000Direct (D) No
F5
  • F5 This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.
Open filing 0001193125-25-326771 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Sachs Jessica Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)50,0000—51,296Direct (D) No
F1
  • F1 Award of Restricted Stock Units (RSUs) under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.
Open filing 0001193125-25-326773 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Sachs Jessica Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)320,0000—371,296Direct (D) No
F2
  • F2 Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the 2023 PSUs).
Open filing 0001193125-25-326773 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Sachs Jessica Officer: Chief Medical Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)154,71639.45
6,103,546.2

Derived: shares × price per share. Exact value 6103546.20.

216,580Direct (D) No
F3, F4
  • F3 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.
  • F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Open filing 0001193125-25-326773 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Sachs Jessica Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (65,000) — exercise price 39.45
Acquired (A)65,0000.00
0

Derived: shares × price per share. Exact value 0.00.

65,000Direct (D) No
F5
  • F5 This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.
Open filing 0001193125-25-326773 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Robinson John Edward Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)50,0000—50,000Direct (D) No
F1
  • F1 Award of Restricted Stock Units (RSUs) under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.
Open filing 0001193125-25-326776 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Robinson John Edward Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)320,0000—370,000Direct (D) No
F2
  • F2 Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the 2023 PSUs).
Open filing 0001193125-25-326776 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Robinson John Edward Officer: Chief Scientific Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)139,99839.45
5,522,921.1

Derived: shares × price per share. Exact value 5522921.10.

230,002Direct (D) No
F3, F4
  • F3 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.
  • F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Open filing 0001193125-25-326776 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Robinson John Edward Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (65,000) — exercise price 39.45
Acquired (A)65,0000.00
0

Derived: shares × price per share. Exact value 0.00.

65,000Direct (D) No
F5
  • F5 This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.
Open filing 0001193125-25-326776 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Kearns Evan Officer: Chief Legal Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)40,0000—40,000Direct (D) No
F1
  • F1 Award of Restricted Stock Units (RSUs) under the Issuer's 2018 Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date, subject to the Reporting Person's continuing service with the Issuer through such dates.
Open filing 0001193125-25-326772 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Kearns Evan Officer: Chief Legal Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)260,0000—300,000Direct (D) No
F2
  • F2 Represents acquisition of shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the 2023 PSUs).
Open filing 0001193125-25-326772 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Kearns Evan Officer: Chief Legal Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)125,60239.45
4,954,998.9

Derived: shares × price per share. Exact value 4954998.90.

174,398Direct (D) No
F3, F4
  • F3 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings in connection with the vesting of the 2023 PSUs.
  • F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Open filing 0001193125-25-326772 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19Kearns Evan Officer: Chief Legal Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (55,000) — exercise price 39.45
Acquired (A)55,0000.00
0

Derived: shares × price per share. Exact value 0.00.

55,000Direct (D) No
F5
  • F5 This stock option shall vest in equal monthly installments over a four year period, subject to the Reporting Person's continuing service to the Issuer through such dates.
Open filing 0001193125-25-326772 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–27 of 27

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Linden Advisors LP 83,909,000 PRN91,220,134 dollarsLower by 5,256,000 Prior quarter: 89,165,000Open filing 0001193125-26-462390 Filed 2026-11-16 Dispute this row
WOLVERINE ASSET MANAGEMENT LLC Partly reported under another manager40,031,000 PRN43,122,830 dollarsHigher by 10,531,000 Prior quarter: 29,500,000Open filing 0001279891-26-000016 Filed 2026-11-02 Dispute this row
Calamos Advisors LLC 15,341,000 PRN16,562,911 dollarsLower by 2,073,000 Prior quarter: 17,414,000Open filing 0001316507-26-000004 Filed 2026-11-02 Dispute this row
READYSTATE ASSET MANAGEMENT LP 12,500,000 PRN13,481,250 dollarsHigher by 10,000,000 Prior quarter: 2,500,000Open filing 0001214659-26-014366 Filed 2026-11-16 Dispute this row
Affinity Asset Advisors, LLC 11,000,000 PRN12,054,793 dollarsUnchanged Prior quarter: 11,000,000Open filing 0001011438-26-000687 Filed 2026-11-13 Dispute this row
BROOKFIELD Corp /ON/ Partly reported under another manager9,802,000 PRN10,741,916 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-467250 Filed 2026-11-18 Dispute this row
LORD, ABBETT CO. LLC 8,141,000 PRN8,900 dollarsLower by 11,000 Prior quarter: 8,152,000Open filing 0000930413-26-003314 Filed 2026-11-13 Dispute this row
Wellesley Asset Management 7,550,000 PRN6,013,841 dollarsHigher by 300,000 Prior quarter: 7,250,000Open filing 0001533551-26-000009 Filed 2026-11-12 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager6,000,000 PRN6,582,175 dollarsUnchanged Prior quarter: 6,000,000Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
ADVENT CAPITAL MANAGEMENT /DE/ 4,302,000 PRN4,740,930 dollarsLower by 163,000 Prior quarter: 4,465,000Open filing 0001140361-26-042650 Filed 2026-11-09 Dispute this row
GABELLI FUNDS LLC 4,250,000 PRN4,588,513 dollarsNot in the prior quarter’s filings read Open filing 0001140361-26-043450 Filed 2026-11-12 Dispute this row
Jefferies Financial Group Inc. Partly reported under another manager4,097,000 PRN4,415,212 dollarsHigher by 3,943,000 Prior quarter: 154,000Open filing 0000096223-26-000034 Filed 2026-11-05 Dispute this row
SSI INVESTMENT MANAGEMENT LLC 3,897,000 PRN4,251,201 dollarsLower by 356,000 Prior quarter: 4,253,000Open filing 0001172661-26-004930 Filed 2026-11-10 Dispute this row
MILLENNIUM MANAGEMENT LLC 2,000,000 PRN2,153,264 dollarsUnchanged Prior quarter: 2,000,000Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager1,535,000 PRN1,674,517 dollarsUnchanged Prior quarter: 1,535,000Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager1,103,000 PRN1,203,252 dollarsHigher by 3,000 Prior quarter: 1,100,000Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
AGF MANAGEMENT LTD Partly reported under another manager1,000,000 PRN1,090,890 dollarsUnchanged Prior quarter: 1,000,000Open filing 0000945621-26-001335 Filed 2026-11-03 Dispute this row
Kohlberg Kravis Roberts Co. L.P. Partly reported under another manager500,000 PRN547,945 dollarsLower by 490,000 Prior quarter: 990,000Open filing 0001399770-26-000010 Filed 2026-11-13 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager438,000 PRN477,810 dollarsUnchanged Prior quarter: 438,000Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
Calamos Wealth Management LLC 290,000 PRN313,099 dollarsHigher by 22,000 Prior quarter: 268,000Open filing 0001455258-26-000004 Filed 2026-11-02 Dispute this row
LAZARD ASSET MANAGEMENT LLC 262,000 PRN2,871 dollarsUnchanged Prior quarter: 262,000Open filing 0001207017-26-000051 Filed 2026-11-16 Dispute this row
Central Pacific Bank - Trust Division Partly reported under another manager230,000 PRN250,905 dollarsUnchanged Prior quarter: 230,000Open filing 0002020066-26-000006 Filed 2026-10-06 Dispute this row
GROUP ONE TRADING LLC Option: Call 58,600 SH1,876,372 dollarsLower by 111,000 Prior quarter: 169,600Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row
SIMPLEX TRADING, LLC Option: Call 42,100 SH1,348,042 dollarsLower by 19,000 Prior quarter: 61,100Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row
HRT FINANCIAL LP 35,000 SH1,120 dollarsHigher by 25,000 Prior quarter: 10,000Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
SIMPLEX TRADING, LLC Option: Put 24,000 SH768,480 dollarsLower by 20,600 Prior quarter: 44,600Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row
GROUP ONE TRADING LLC Option: Put 18,200 SH582,764 dollarsHigher by 4,200 Prior quarter: 14,000Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Jump Financial, LLC 11,944,000 PRN
  • OAKTREE CAPITAL MANAGEMENT LP 11,890,000 PRN
  • Jupiter Topco LLC 3,922,000 SH
  • ORBIMED ADVISORS LLC 1,000,000 PRN
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

Showing 1–1 of 1

House members’ trades in this company, newest report first, as filed
MemberTransaction dateTypeAmountOwnerReport
Hon. Christopher L. Jacobs (NY27)2022-12-12Purchase$1,001 - $15,0002023-01-20

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Deerfield Mgmt, L.P. Common Stock2.885,006,104.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 2Open filing 0001193805-26-001082 Dispute this row
Deerfield Management Company, L.P. Common Stock2.885,006,104.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 2Open filing 0001193805-26-001082 Dispute this row
Deerfield Partners, L.P. Common Stock2.885,006,104.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 2Open filing 0001193805-26-001082 Dispute this row
James E. Flynn Common Stock2.885,006,104.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 2Open filing 0001193805-26-001082 Dispute this row
Vanguard Capital Management Common Stock5.088,691,58906/30/2026 Filed 2026-07-31SCHEDULE 13GOpen filing 0002100119-26-001323 Dispute this row
BlackRock, Inc. Common Stock8.013,593,06306/30/2026 Filed 2026-07-27SCHEDULE 13G/AAmendment 3Open filing 0002012383-26-002235 Dispute this row
Deerfield Mgmt, L.P. Common Stock5.299,043,903.0003/31/2026 Filed 2026-05-14SCHEDULE 13G/AAmendment 1Open filing 0001193805-26-000609 Dispute this row
Deerfield Management Company, L.P. Common Stock5.299,043,903.0003/31/2026 Filed 2026-05-14SCHEDULE 13G/AAmendment 1Open filing 0001193805-26-000609 Dispute this row
Deerfield Partners, L.P. Common Stock5.299,043,903.0003/31/2026 Filed 2026-05-14SCHEDULE 13G/AAmendment 1Open filing 0001193805-26-000609 Dispute this row
James E. Flynn Common Stock5.299,043,903.0003/31/2026 Filed 2026-05-14SCHEDULE 13G/AAmendment 1Open filing 0001193805-26-000609 Dispute this row
Fairmount Funds Management LLC Common Stock, $0.001 par value8.615,356,918.0003/31/2026 Filed 2026-03-31SCHEDULE 13D/AAmendment 10Open filing 0001104659-26-038056 Dispute this row
Fairmount Healthcare Fund II GP LLC Common Stock, $0.001 par value8.615,356,918.0003/31/2026 Filed 2026-03-31SCHEDULE 13D/AAmendment 10Open filing 0001104659-26-038056 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 2Open filing 0000102909-26-000905 Dispute this row
Fairmount Funds Management LLC Common Stock, $0.001 par value9.916,261,918.0001/22/2026 Filed 2026-01-22SCHEDULE 13D/AAmendment 9Open filing 0001104659-26-005917 Dispute this row
Fairmount Healthcare Fund II GP LLC Common Stock, $0.001 par value9.916,261,918.0001/22/2026 Filed 2026-01-22SCHEDULE 13D/AAmendment 9Open filing 0001104659-26-005917 Dispute this row
Kynam Capital Management, LP Common Stock, par value $0.0014.336,165,22312/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001907884-26-000002 Dispute this row
Kynam Capital Management GP, LLC Common Stock, par value $0.0014.336,165,22312/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001907884-26-000002 Dispute this row
Yue Tang Common Stock, par value $0.0014.336,165,22312/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001907884-26-000002 Dispute this row
Commodore Capital LP Common Stock, $0.001 par value per share1.82,802,905.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001831942-26-000011 Dispute this row
Commodore Capital Master LP Common Stock, $0.001 par value per share1.82,802,905.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001831942-26-000011 Dispute this row
Robert Egen Atkinson Common Stock, $0.001 par value per share1.82,802,905.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001831942-26-000011 Dispute this row
Michael Kramarz Common Stock, $0.001 par value per share1.82,802,905.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001831942-26-000011 Dispute this row
The Vanguard Group Common Stock7.5011,514,32612/31/2025 Filed 2026-01-30SCHEDULE 13G/AAmendment 1Open filing 0000102909-26-000056 Dispute this row
BlackRock, Inc. Common Stock6.511,370,224.0012/31/2025 Filed 2026-01-21SCHEDULE 13G/AAmendment 2Open filing 0002012383-26-000802 Dispute this row
BlackRock, Inc. Common Stock6.511,370,22412/31/2025 Filed 2026-01-21SCHEDULE 13G/AAmendment 2Open filing 0002012383-26-000657 Dispute this row
Fairmount Funds Management LLC Common Stock, $0.001 par value9.915,877,418.0011/13/2025 Filed 2025-11-17SCHEDULE 13D/AAmendment 8Open filing 0001104659-25-113219 Dispute this row
Fairmount Healthcare Fund II GP LLC Common Stock, $0.001 par value9.915,877,418.0011/13/2025 Filed 2025-11-17SCHEDULE 13D/AAmendment 8Open filing 0001104659-25-113219 Dispute this row
Commodore Capital LP Common Stock, $0.001 Par Value7.210,208,060.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001831942-25-000029 Dispute this row
Commodore Capital Master LP Common Stock, $0.001 Par Value7.210,208,060.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001831942-25-000029 Dispute this row
Robert Egen Atkinson Common Stock, $0.001 Par Value7.210,208,060.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001831942-25-000029 Dispute this row
Michael Kramarz Common Stock, $0.001 Par Value7.210,208,060.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001831942-25-000029 Dispute this row
Point72 Asset Management, L.P. Common Stock, par value $0.001 per share4.05,753,833.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0000902664-25-005033 Dispute this row
Point72 Capital Advisors, Inc. Common Stock, par value $0.001 per share4.05,753,833.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0000902664-25-005033 Dispute this row
Steven A. Cohen Common Stock, par value $0.001 per share4.05,753,833.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0000902664-25-005033 Dispute this row
Paradigm BioCapital Advisors LP Common Stock, $0.001 par value per share2.33,156,398.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001104659-25-112634 Dispute this row
Paradigm BioCapital Advisors GP LLC Common Stock, $0.001 par value per share2.33,156,398.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001104659-25-112634 Dispute this row
Senai Asefaw, M.D. Common Stock, $0.001 par value per share2.33,156,398.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001104659-25-112634 Dispute this row
Paradigm BioCapital International Fund Ltd. Common Stock, $0.001 par value per share2.02,786,647.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0001104659-25-112634 Dispute this row
Kynam Capital Management, LP Common Stock, par value $0.0015.547,886,17209/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001907884-25-000004 Dispute this row
Kynam Capital Management GP, LLC Common Stock, par value $0.0015.547,886,17209/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001907884-25-000004 Dispute this row
Yue Tang Common Stock, par value $0.0015.547,886,17209/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 1Open filing 0001907884-25-000004 Dispute this row
TCG Crossover GP I, LLC Common Stock, par value $0.001 per share4.86,798,16209/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001193125-25-283076 Dispute this row
TCG Crossover Fund I, L.P. Common Stock, par value $0.001 per share4.86,798,16209/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001193125-25-283076 Dispute this row
Chen Yu Common Stock, par value $0.001 per share4.86,798,16209/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001193125-25-283076 Dispute this row
Fairmount Funds Management LLC Common Stock, $0.001 par value9.914,324,918.0007/10/2025 Filed 2025-07-14SCHEDULE 13D/AAmendment 7Open filing 0001104659-25-067760 Dispute this row
Fairmount Healthcare Fund II GP LLC Common Stock, $0.001 par value9.914,324,918.0007/10/2025 Filed 2025-07-14SCHEDULE 13D/AAmendment 7Open filing 0001104659-25-067760 Dispute this row
Commodore Capital LP Common Stock, $0.001 Par Value5.56,408,060.0007/07/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001831942-25-000016 Dispute this row
Commodore Capital Master LP Common Stock, $0.001 Par Value5.56,408,060.0007/07/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001831942-25-000016 Dispute this row
Robert Egen Atkinson Common Stock, $0.001 Par Value5.56,408,060.0007/07/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001831942-25-000016 Dispute this row
Michael Kramarz Common Stock, $0.001 Par Value5.56,408,060.0007/07/2025 Filed 2025-08-14SCHEDULE 13GOpen filing 0001831942-25-000016 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,708,462 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015124,844
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to COGENT BIOSCIENCES, INC.